Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects

NCT ID: NCT01633944

Last Updated: 2017-02-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

752 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if buprenorphine hydrochloride (HCl) buccal film is effective in treating opioid-naive subjects, with moderate to severe chronic low back pain (CLBP), who require continuous around-the-clock (ATC) pain relief for an extended period of time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Twice Daily Dosing

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching Placebo Buccal Film twice daily

Buprenorphine HCl Buccal Film

Twice Daily Dosing

Group Type EXPERIMENTAL

Buprenorphine

Intervention Type DRUG

Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buprenorphine

Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily

Intervention Type DRUG

Placebo

Matching Placebo Buccal Film twice daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BELBUCA Buprenorphine HCl Buccal Film BEMA Buprenorphine EN3409 Placebo Buccal Film BEMA Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of moderate to severe low back pain for ≥6 months
* Treating CLBP with a stable daily maintenance dose of non-opioid analgesic medication up to 10 mg morphine sulfate equivalents (MSE) per day for ≥4 weeks. (Additional as needed \[PRN\] non-opioid analgesic medications permitted on top of the stable daily maintenance dose of non-opioid analgesic)
* Stable health, as determined by Principal Investigator
* Are female who are practicing abstinence or using a medically acceptable form of contraception or have been post-menopausal, biologically sterile, or surgically sterile for more than 1 year
* Willing and able to comply with all protocol required visits and assessments

Exclusion Criteria

* Current cancer related pain or received chemotherapy with 6 months of screening
* Receiving opioid analgesic medication \>10 mg MSE per day within 28 days of screening
* Subjects with a history of other chronic painful conditions
* Reflex sympathetic dystrophy or causalgia, acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis
* Allergy or contraindications to any opioid or acetaminophen
* Surgical procedure for relief of pain with 6 months
* Hypokalemia or clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia
* QT interval corrected using Fridericia's formula (QTcF) of ≥450 milliseconds on the 12-lead electrocardiogram (ECG)
* History of long QT syndrome or a family member with this condition
* Moderate to severe hepatic impairment
* Moderate to severe renal impairment
* Current or past history of alcohol abuse
* Positive urine toxicology screen for drug of abuse
* History or abnormalities on physical exam, vital signs, electrocardiogram, or laboratory values
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioDelivery Sciences International

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

M. Todd Kirby, PhD

Role: STUDY_DIRECTOR

Endo Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Horizon Research Group, Inc./Alabama Orthopedic Clinic

Mobile, Alabama, United States

Site Status

Arizona Research Center

Phoenix, Arizona, United States

Site Status

Global Research

Anaheim, California, United States

Site Status

Catalina Research Institute, LLC

Chino, California, United States

Site Status

Synergy Clinical Research Center of Escondido

Escondido, California, United States

Site Status

Adam D. Karns MD

Los Angeles, California, United States

Site Status

Stamford Therapeutics Consortium

Stamford, Connecticut, United States

Site Status

Clinical Research of West Florida - Clearwater

Clearwater, Florida, United States

Site Status

Century Clinical Research, Inc.

Daytona Beach, Florida, United States

Site Status

Avail Clinical Research, LLC

DeLand, Florida, United States

Site Status

Florida Health Center

Fort Lauderdale, Florida, United States

Site Status

Eastern Research, Inc.

Hialeah, Florida, United States

Site Status

Florida Institute of Medical Research

Jacksonville, Florida, United States

Site Status

Drug Study Institute

Jupiter, Florida, United States

Site Status

Health Awareness, Inc.

Jupiter, Florida, United States

Site Status

NEMA Research, Inc.

Naples, Florida, United States

Site Status

Compass Research, LLC

Orlando, Florida, United States

Site Status

Peninsula Research

Ormond Beach, Florida, United States

Site Status

Gold Coast Research, L.L.C.

Plantation, Florida, United States

Site Status

Progressive Medical Research

Port Orange, Florida, United States

Site Status

Clinical Research of West Florida - Tampa

Tampa, Florida, United States

Site Status

National Pain Research Institute, LLC

Winter Park, Florida, United States

Site Status

Atlanta Research Center

Atlanta, Georgia, United States

Site Status

River Birch Research Alliance, LLC

Blue Ridge, Georgia, United States

Site Status

Drug Studies America

Marietta, Georgia, United States

Site Status

Georgia Institute for Clinical Research, LLC

Marietta, Georgia, United States

Site Status

Taylor Research, LLC

Marietta, Georgia, United States

Site Status

MediSphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Integrated Clinical Trial Services, Inc.

West Des Moines, Iowa, United States

Site Status

International Clinical Research Institute, Inc.

Overland Park, Kansas, United States

Site Status

Willis-Kinghton Physician Network/River Interventional Pain Specialist

Bossier City, Louisiana, United States

Site Status

Clinical Trials Management, LLC

Metairie, Louisiana, United States

Site Status

Best Clinical Trials, Inc.

New Orleans, Louisiana, United States

Site Status

River Cities Clinical Research Center

Shreveport, Louisiana, United States

Site Status

MedVadis Research Corp.

Watertown, Massachusetts, United States

Site Status

Great Lakes Research Group, Inc.

Bay City, Michigan, United States

Site Status

The Center for Clinical Trials

Biloxi, Mississippi, United States

Site Status

Office of Robert Kaplan, DO

Las Vegas, Nevada, United States

Site Status

Long Island Gastrointestinal Research Group

Great Neck, New York, United States

Site Status

Upstate Clinical Research Associates LLC

Williamsville, New York, United States

Site Status

PharmQuest, LLC

Greensboro, North Carolina, United States

Site Status

The Center for Clinical Research

Winston-Salem, North Carolina, United States

Site Status

Plains Medical Clinic, LLC

Fargo, North Dakota, United States

Site Status

Clinical Inquest Center, Ltd.

Beavercreek, Ohio, United States

Site Status

New Horizons Clinical Research

Cincinnati, Ohio, United States

Site Status

Optimed Research, Ltd.

Columbus, Ohio, United States

Site Status

Prestige Clinical Research

Franklin, Ohio, United States

Site Status

Health Research Institute

Oklahoma City, Oklahoma, United States

Site Status

NPC Research

Oklahoma City, Oklahoma, United States

Site Status

Brandywine Clinical Research

Downingtown, Pennsylvania, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Health Concepts

Rapid City, South Dakota, United States

Site Status

FutureSearch Clinical Trials - Austin

Austin, Texas, United States

Site Status

KRK Medical Research

Dallas, Texas, United States

Site Status

FutureSearch Trials of Dallas, LP

Dallas, Texas, United States

Site Status

Advanced Clinical Research of Houston

Houston, Texas, United States

Site Status

Clinical Trial Network

Houston, Texas, United States

Site Status

Innovative Clinical Trials

San Antonio, Texas, United States

Site Status

Highland Clinical Research

Salt Lake City, Utah, United States

Site Status

Clinical Investigations Specialists, Inc.

Kenosha, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EN3409-308

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.